J&J Hit With $1.75M Verdict In 4th Philly Risperdal Case

By Matt Fair (November 9, 2015, 3:41 PM EST) -- A Johnson & Johnson unit was slapped with a $1.75 million verdict in Pennsylvania state court on Monday in a fourth case alleging the company failed to properly disclose the risks of abnormal breast growth in adolescent boys using the antipsychotic drug Risperdal....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!